Correlation Between Vivos Therapeutics and NextCure

Can any of the company-specific risk be diversified away by investing in both Vivos Therapeutics and NextCure at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Vivos Therapeutics and NextCure into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Vivos Therapeutics and NextCure, you can compare the effects of market volatilities on Vivos Therapeutics and NextCure and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Vivos Therapeutics with a short position of NextCure. Check out your portfolio center. Please also check ongoing floating volatility patterns of Vivos Therapeutics and NextCure.

Diversification Opportunities for Vivos Therapeutics and NextCure

-0.79

Correlation Coefficient

Vivos Therapeutics  NextCure

Pay attention - limited upside

The 3 months correlation between Vivos and NextCure is -0.79. Overlapping area represents the amount of risk that can be diversified away by holding Vivos Therapeutics and NextCure in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on NextCure and Vivos Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Vivos Therapeutics are associated (or correlated) with NextCure. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of NextCure has no effect on the direction of Vivos Therapeutics i.e., Vivos Therapeutics and NextCure go up and down completely randomly.

Pair Corralation between Vivos Therapeutics and NextCure

Given the investment horizon of 90 days Vivos Therapeutics is expected to under-perform the NextCure. But the stock apears to be less risky and, when comparing its historical volatility, Vivos Therapeutics is 2.0 times less risky than NextCure. The stock trades about -0.26 of its potential returns per unit of risk. The NextCure is currently generating about 0.17 of returns per unit of risk over similar time horizon. If you would invest  522.00  in NextCure on August 23, 2025 and sell it today you would earn a total of  529.00  from holding NextCure or generate 101.34% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Weak
Accuracy	100.0%
Values	Daily Returns

Vivos Therapeutics  vs.  NextCure

Vivos Therapeutics

Risk-Adjusted Performance

Weakest

Over the last 90 days Vivos Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in December 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.

NextCure

Risk-Adjusted Performance

Good

Compared to the overall equity markets, risk-adjusted returns on investments in NextCure are ranked lower than 13 (%) of all global equities and portfolios over the last 90 days. In spite of rather weak basic indicators, NextCure exhibited solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Vivos Therapeutics and NextCure

The main advantage of trading using opposite Vivos Therapeutics and NextCure positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Vivos Therapeutics position performs unexpectedly, NextCure can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in NextCure will offset losses from the drop in NextCure's long position.

The idea behind Vivos Therapeutics and NextCure pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.